Enrolment Started For LUX-Lung 1 Study Oncology Research Programme

Boehringer Ingelheim is making progress in its oncology research programme, particularly in the most common form of lung cancer, non-small cell lung cancer (NSCLC). The first pivotal study for BIBW 2992 has now begun patient enrolment. The LUX-Lung 1 study is a randomized, double-blind phase IIb/III study. It will aim to determine the efficacy of BIBW 2992 plus best supportive care (BSC) compared to placebo plus BSC.

More: continued here

Filed under: Lung Cancer on June 10th, 2008